You are here: Home: CACU 1 | 2008: Faculty Disclosures
CONTENT VALIDATION AND DISCLOSURES
Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the Research To Practice scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice reported real or apparent conflicts of interest for themselves (or their spouses/partners), which have been resolved through a conflict of interest resolution process: Aviva Asnis-Alibozek, PA-C, MPAS — Salary: AstraZeneca Pharmaceuticals LP; Shareholder of: AstraZeneca Pharmaceuticals LP; Sally Bogert, RNC, WHCNP — Shareholder of: Amgen Inc and Genentech BioOncology. All other Research To Practice staff and external reviewers: No real or apparent conflicts of interest to report.
FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Gregory — Consulting Fees: Genentech BioOncology; Contracted Research: Genentech BioOncology, GlaxoSmithKline; Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, Millennium Pharmaceuticals Inc. Dr Richardson — Speakers Bureau: Celgene Corporation, Millennium Pharmaceuticals Inc.
This educational activity contains discussion of published and/or investigational uses of agents that are
not indicated by the Food and Drug Administration. Research To Practice does not recommend the use
of any agent outside of the labeled indications. Please refer to the official prescribing information for each
product for discussion of approved indications, contraindications and warnings. The opinions expressed
are those of the presenters and are not to be construed as those of the publisher or grantors.
|